2-year follow-up of a randomized controlled trial of everolimus- and paclitaxel-eluting stents for coronary revascularization in daily practice. COMPARE (Comparison of the everolimus eluting XIENCE-V stent with the paclitaxel eluting TAXUS LIBERTÉ stent in all-comers: a randomized open label trial).

@article{Smits20112yearFO,
  title={2-year follow-up of a randomized controlled trial of everolimus- and paclitaxel-eluting stents for coronary revascularization in daily practice. COMPARE (Comparison of the everolimus eluting XIENCE-V stent with the paclitaxel eluting TAXUS LIBERT{\'E} stent in all-comers: a randomized open label trial).},
  author={P. C. Smits and Elvin Kedhi and Kees-Jan Royaards and Kaiyum Sheik Joesoef and Jochem Wassing and Tessa A M Rademaker-Havinga and Eug{\`e}ne McFadden},
  journal={Journal of the American College of Cardiology},
  year={2011},
  volume={58 1},
  pages={11-8}
}
OBJECTIVES The purpose of this study was to compare the safety and efficacy of the Xience V (Abbott Vascular, Santa Clara, California) everolimus-eluting stent (EES) with the Taxus Liberté (Boston Scientific, Natick, Massachusetts) paclitaxel-eluting stent (PES) at 2-year follow-up. BACKGROUND COMPARE (Comparison of the everolimus eluting XIENCE-V stent with the paclitaxel eluting TAXUS LIBERTÉ stent in all-comers: a randomized open label trial) demonstrated a superior clinical outcome of EES… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 92 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 13 references

Similar Papers

Loading similar papers…